[ad_1]
US well being authorities on Thursday accepted the world’s first vaccine for chikungunya, a virus unfold by contaminated mosquitoes that the Food and Drug Administration known as “an emerging global health threat.”
The vaccine, developed by Europe’s Valneva which can be marketed beneath the identify Ixchiq, was accepted for individuals 18 and over who’re at elevated danger of publicity, the FDA mentioned.
Ixchiq’s green-light by the US drug regulator is predicted to hurry the vaccine’s rollout in nations the place the virus is most prevalent.
Chikungunya, which causes fever and extreme joint ache, is most prevalent in tropical and subtropical areas of Africa, southeast Asia and a part of the Americas.
“However, chikungunya virus has spread to new geographical areas causing a rise in global prevalence of the disease,” the FDA mentioned, reporting greater than 5 million circumstances previously 15 years.
“Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions,” senior FDA official Peter Marks mentioned in a press release.
“Today’s approval addresses an unmet medical need and is an important advancement in the prevention of a potentially debilitating disease with limited treatment options.”
The vaccine is injected in a single dose and accommodates a dwell, weakened model of the chikungunya virus, as is normal with different vaccines.
Two medical trials have been carried out in North America on 3,500 individuals. Headache, fatigue, muscle and joint ache, fever and nausea have been generally reported unwanted side effects.
Serious reactions have been reported in 1.6 % of Ixchiq recipients within the trials, with two requiring hospitalization.
Subscribe in the present day by clicking the hyperlink and keep up to date with the most recent information! Click here!Get Latest World News together with Latest News from India at Hindustan Times.
[adinserter block=”4″]
[ad_2]
Source link